Register for this webinar to learn about SARS-COV-2 variant testing. With your registration, you will have access to the recording on demand through October 31, 2022.
The science on and surrounding SARS-COV-2 and the application of laboratory medicine towards combating the pandemic has evolved at a blistering, unprecedented pace. The majority of the first year of the pandemic focused on the development and deployment of multiple test modalities for the detection of SARS-COV-2, from PCR to Antigen, as the world as a whole strived to develop a vaccine in record time. Now as we enter the second year of the SARS-COV-2 pandemic, focus shifts to understanding our new vaccine-induced immunity and the continued development and spread of SARS-COV-2 variants. Major issues faced by laboratory medicine include the role of serology testing in a vaccinated population with the goal of identifying a true correlate of immunity, and the possible effects of variants on viral detection methods. The designated roles of public health and clinical laboratories as well as the lines between surveillance, screening, and diagnostic testing continues to blur for many health systems. This webinar strives to provide attendees with a condensed yet comprehensive understanding on these two issues from experts in the field facing these challenges on a daily basis. Because information and developments on SARS-COV-2 is so fragmented even in the scientific landscape, this webinar assists in amalgamating current knowledge on the current and upcoming use of serology and variant testing in the SARS-COV-2 pandemic.
Over the past year, clinical laboratories throughout the world have been faced with an ever-evolving and rapidly changing landscape. Recently, the rise of multiple SARS-COV-2 variants threatens to impact established viral detection methods and often blurs the lines between public health epidemiology efforts and traditional hospital-based diagnostic testing.
This activity is designed for physicians, point-of-care coordinators, lab directors, assistant directors, pathologists, fellows, residents, in-training individuals, other laboratory professionals overseeing/conducting SARS-COV-2 testing.
At the end of this activity, participants will be able to:
- Identify when the use-case scenario supports targeted (defined variants) vs full sequencing (novel identification) testing modalities.
- Describe the capability of the majority of commercially available testing platforms to detect SARS-COV-2 variant infections.
- Develop a framework for coordination between the clinical laboratories and public health entities in identification and tracking of SARS-COV-2 variants.
Jessica Crothers, MD
University of Vermont Medical Center; University of Vermont Larner College of Medicine
DISCLOSURES AND STATEMENT OF INDEPENDENCE
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to AACC and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the continuing education content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. AACC has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty member listed below reported the following relevant financial relationship(s) during the content development process for this activity:
Jessica Crothers, MD
Consultant Fees; Finch Therapeutics
The following planning member- reported no relevant financial relationship(s) during the content development process for this activity:
Clayton Wilburn, MD, DABCC
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
American Association for Clinical Chemistry (AACC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. This educational activity is designated for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This education activity is approval for up to 1.0 ACCENT credit(s).
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter.
SUCCESSFUL COMPLETION STATEMENT
CE/CME certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].
RELEASE DATE: October 20, 2021
EXPIRATION DATE: October 31, 2022 (date after which this activity is no longer certified for continuing education credit)